This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: Schurmann 94, 95 , Wouter den Hollander 96 , Tarunveer S Ahluwalia 97, 98 , Jing Zhao 99 , Harmen HM Phone: 0031 50 361 0738, Fax: 0031 50 361 4493 C-reactive protein (CRP) is a sensitive biomarker of chronic low-grade inflammation that is associated with multiple complex diseases. The genetic determinants of chronic inflammation remain largely unknown, and the causal role of CRP in several clinical outcomes is debated. We performed two genomewide association studies (GWAS), HapMap and 1000Genomes imputed, of circulating CRP levels using data from 88 studies comprising 204,402 European individuals. Additionally, we performed in silico functional analyses and Mendelian randomization analyses with several clinical outcomes. The GWAS meta-analyses of CRP revealed 58 distinct genetic loci (P<5×10 -8 ). After adjustment for body mass index in the regression analysis, the associations at all except three loci remained. The lead variants at the distinct loci explained up to 7.0% of the variance in circulating CRP levels. We identified 66 gene sets that were organized in two substantially correlated clusters, one mainly comprised of immune pathways, and the other characterized by metabolic pathways in the liver. Mendelian randomization analyses revealed a causal protective effect of CRP on schizophrenia and a risk increasing effect on bipolar disorder. Our findings provide further insights in the biology of inflammation that may lead to interventions to treat inflammation and its clinical consequences.
Introduction
Inflammation plays a key role in the development of complex diseases such as cardiovascular disease 1 , type 2 diabetes 2 , Alzheimer's disease 3 , and schizophrenia 4 . C-reactive protein (CRP) is a sensitive marker of chronic low-grade inflammation 5 , and elevated serum levels of CRP have been associated with a wide range of diseases [6] [7] [8] . Unraveling the genetics of inflammation may provide further insights into the underlying biology of inflammation, and may identify therapeutic targets to attenuate inflammation.
The genetic determinants of CRP have only been partly characterized. In 2011, our group published a HapMap-based meta-analysis of genome-wide association studies (GWAS) including a discovery panel of up to 65,000 individuals and found 18 loci that were associated with CRP levels 9 .
Increasing study sample size in GWAS and denser mapping of the genome with further advanced imputation panels may help to identify further genes associated with the phenotypes of interest 10; 11 .
Furthermore, by using genetic instrumental variables (i.e., a genetic score), Mendelian randomization (MR) allows investigation of the potential causal effect of an exposure on clinical outcomes, and may help to understand the causal pathways that link the exposure with the outcome 12 . The causal role of CRP in the development of diseases is still controversial 13 , and the causal pathways that link inflammation to complex disorders are only partly understood.
We applied two large-scale GWAS on circulatory levels of CRP using HapMap and 1000Genomes (1KG) imputed data to identify genetic determinants of chronic inflammation. Because body mass index (BMI) is a major determinant of CRP levels, we additionally conducted GWAS adjusted for BMI to identify associated loci independent of BMI. To identify any sex differences in genetic determinants of chronic inflammation, we further conducted GWAS in men and women separately. We applied in silico functional analyses on the identified loci to obtain better insights into the biological processes potentially regulating chronic inflammation. Finally, we conducted MR analyses to provide an improved understanding of the causal relation between CRP and several related clinical outcomes.
Material and methods

GWAS for circulating CRP levels
We conducted a meta-analysis of GWAS including individuals of European ancestry within the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium Inflammation Working Group of the (CIWG) 14 . The CIWG invited cohorts for participation in the HapMap GWAS meta-analysis of CRP levels in 2012. In 2014 and in light of our assessment which showed complementary value of HapMap and 1KG imputed GWAS 10 , we invited studies to participate in the 1KG GWAS meta-analysis. The 1KG GWAS may help to identify loci that were not covered in the HapMap GWAS and fine map loci found in the HapMap GWAS. Cohorts were allowed to participate in either the HapMap or 1KG GWAS, or both.
Here we present both a HapMap (204,402 individuals from 78 studies) and 1KG (148,164 individuals from 49 studies) imputed genotypes GWAS meta-analysis. All participating cohorts implemented a prespecified study plan comprising study design, data quality check, data analysis, and data sharing. We measured serum CRP in mg/L using standard laboratory techniques (Supplemental Methods), and natural log-transformed the values. Individuals with auto-immune diseases, individuals taking immunemodulating agents (if this information was available), and individuals with CRP levels 4SD or more away from the mean were excluded from all analyses. The characteristics of the participants are presented in Table S1 . We filtered individuals and genetic variants based on study-specific quality control criteria (Table S2 ). At each individual study site, we tested genetic variants for association with CRP levels using an additive linear regression model adjusted for age, sex, and population substructure, and accounting for relatedness, if relevant. Before meta-analysis, we filtered variants based on imputation quality at R 2 index of >0.4. To avoid type-I error inflation, we corrected study-specific GWAS for genomic inflation. For the HapMap study, we conducted fixed effect meta-analyses for each genetic variant, using the inverse variance-weighted method implemented in GWAMA 15 , and performed a second genomic control on the meta-analysis level. For the 1KG imputed GWAS, we used METAL 16 to perform a fixed effect metaanalysis. We removed variants that were only available in <50% of the samples. The HapMap metaanalysis included 2,437,193 variants, and the 1KG GWAS included 10,019,203 variants. We considered associations with P<5×10 -8 genome-wide significant. We used a stringent distance criterion, 500kb minimum between two significant variants, to identify distinct loci. In each locus, the variant with the smallest p-value was called the "lead variant". Additionally, we performed sex-stratified analyses among HapMap imputed studies, and we tested for heterogeneity between sex-specific effect estimates as described previously 17 , using the false-discovery rate of Benjamini-Hochberg to assess significance of the P for sex difference (<0.05). We conducted BMI adjusted analyses in the 1KG meta-analysis to determine the role of BMI in mediating the genetic associations with CRP, and to increase power to detect associations not mediated by BMI.
LD Score regression
Because population stratification is a major concern in GWAS and may lead to false-positive associations, we applied Linkage Disequilibrium Score regression (LDSC) to distinguish whether the inflation of test statistics observed in the CRP GWAS is due to the polygenic architecture of CRP or reflects confounding bias due to cryptic relatedness or population stratification. The LD Score measures collective genetic variation acquired from all genetic variants in LD with the index tagging (causal) variant 18 . A higher LD score of an index variant implicates more nearby genetic variants in high LD with the index variant, which makes it more likely that the index variant tags causal variant(s). More genetic variants in LD with the index genetic variant (i.e., a higher LD score due to polygenicity) may yield higher (i.e., inflated) test statistics. In contrast, higher test statistics caused by cryptic population stratification will not be related to LD score. LD Score regression analysis performs regression of the summary statistics from the GWAS meta-analysis (χ 2 statistics from the GWAS) on the LD scores across the genome. An intercept of the LD Score regression that equals one suggests no confounding bias, whereas an inflated intercept (larger than one) suggests contribution of confounding due to relatedness to the test statistics. We used the LDHub web interface to perform LD Score regression 19 . We filtered variants to the subset of HapMap 3 variants, and excluded variants with duplicated rs numbers, ambiguous variants, minor allele frequency (MAF)<0.01, and reported sample size <66.7% of total sample size. We used the default European LD Score file based on the European 1KG reference panel.
Furthermore, we applied cross-trait LD score regression to estimate genetic correlation of chronic inflammation (using the HapMap GWAS meta-analysis) with other phenotypes using published GWAS summary statistics 20 . In brief, the cross-product of two GWAS test statistics is calculated at each genetic variant, and this cross-product is regressed on the LD Score. The slope of the regression is used to estimate the genetic covariance between two phenotypes.
Identification of additional distinct variants in associated loci
To identify additional distinct variants in the associated loci, we performed joint approximate conditional analysis using the 1KG meta-analysis summary statistics and the linkage disequilibrium (LD) matrix derived from the first cohort of the Rotterdam study (RS-I) (n=5,974). We used the Genome-wide Complex Trait Analysis (GCTA) tool, which performs a genome-wide step-wise procedure to identify variants according to their distinct association with CRP (i.e., conditional P) 21; 22 . We only used variants with an imputation quality of R 2 >0.8 in the reference set (RS-I). This approximate conditional analysis may reveal different lead signals in a locus where multiple associated variants are in the final joint association model. We tested the distinct variants identified in the CRP gene jointly for an association with CRP using individual level data from the second and third cohort of the Rotterdam Study (RS-II and RS-III, totaling 5,024 subjects), and the Women's Genome Health Study (WGHS) of 16,299 individuals.
Proportion of CRP variance explained
We estimated the variance explained in serum CRP levels using the formula (2*MAF(1-MAF)beta 2 )/var(CRP), where beta is the estimated effect of the individual variants on CRP 23 and var(CRP) is the variance in natural log-transformed CRP estimated in the RS-I cohort. We calculated the variance explained for four combinations of associated variants: 1. the lead variant at just the CRP locus; 2. the distinct variants at the CRP locus derived from the 1KG joint conditional analysis; 3. all lead variants in the distinct loci; 4. all lead variants in the distinct loci and, when applicable, the distinct variants at associated loci derived from the approximate joint conditional analysis.
Pathway analysis and gene expression
We used Data-Driven Expression-Prioritized Integration for Complex Traits 24 (DEPICT v.1 rel173 beta) to systematically prioritize the most likely causal genes, highlight the pathways that are enriched by the likely causal genes and identify tissues and cell types in which genes from associated loci are highly expressed. DEPICT requires summary statistics from the GWAS meta-analysis. First, we filtered genomewide associated variants from both GWAS meta-analyses by MAF>0.01, and selected variants with low correlation with other variants by PLINK (version 1.90) using a clumping distance of 500 kb apart and/or index of LD r 2 threshold <0.1. The settings for the analysis involved the usage of 1KG pilot phase data 25 (phase 1 integrated release, version 3, CEU, GBR, TSI unrelated individuals; 2010.11.23) with r 2 >0.5 LD threshold for locus definition, 10,000 permutations for bias correction, and 500 repetitions for FDR calculation. To summarize and visualize the results, we calculated pairwise Pearson correlation coefficients between all gene-specific Z-scores for every pair of reconstituted DEPICT gene sets. We used Affinity Propagation Clustering (apcluster command; APCluster R package 26 ). The gene-specific Z-score describes the likelihood that a given gene is part of the corresponding GO term, KEGG pathway, REACTOME pathway, Mouse Phenotype, or protein-protein interaction network.
Also, we performed Multi-marker Analysis of GenoMic Annotation (MAGMA) 28 . MAGMA performs gene and gene-set analysis and requires the association results of all variants, therefore we chose the larger HapMap GWAS for MAGMA. We used the Functional Mapping and Annotation (FUMA) 29 tool to perform MAGMA, and applied standard settings for running MAGMA.
To prioritize the most likely trait-relevant gene for each GWAS locus, we run colocalization analysis using the "coloc" R package v3.1 30 separately for the HapMap and 1KG GWAS. We used publicly available genome-wide eQTL data from 5,311 whole blood samples 31 , and from the Genome Tissue Expression (GTEx) V6p portal incorporating eQTL data from 44 post-mortem tissues 32 . "Coloc" uses approximate Bayes factors to estimate the posterior probability that GWAS and eQTL effects share a single causal variant. All significant cis-eGenes or cis-eProbes (q<0.05 in GTEx; lowest cis-eQTL FDR<0.05 in Westra et al. 31 ) were extracted ±1Mb from the lead SNP of each locus. The HapMap SNP positions were converted to hg19 with the liftOver command from the rtracklayer v1.38.3 package. We used the SNPs present in both the GWAS and eQTL datasets. For the HapMap GWAS, the 1KG GWAS and the GTEx eQTL datasets, we performed the test using association beta, standard error of beta, and minor allele frequency (MAF). For the data from Westra et al. 31 , we used association P-value, MAF, and sample size, and included only the subset of cis-eQTLs which are publicly available (up to significance FDR<0.5). We used default priors supplied by the coloc package (P1=1e-4, P2=1e-4, P12=1e-5; prior probabilities for association in GWAS, eQTL, and both datasets). Full MAF data were not available for the eQTL datasets, therefore we used the GIANT 1KG p1v3 EUR reference panel instead. We visualized the results as a heatmap using the pheatmap v1.0.8 R package. 27 .
Mendelian randomization
To assess the effect of CRP on complex disorders, we performed a two-sample Mendelian randomization (MR) study on nine clinical outcomes (Alzheimer's disease (AD), bipolar disorder (BD), coronary artery disease (CAD), Crohn's disease (CD), inflammatory bowel disease (IBD), rheumatoid arthritis (RA), schizophrenia, and diastolic (DBP) and systolic blood pressure (SBP)) to which CRP showed a potentially causal association at a P<0.1 in a previous MR study 13 . We used the effect estimates of the 48 lead SNPs found to be associated with CRP in the HapMap GWAS, and the effect estimates of the four SNPs that were additionally found to be associated with CRP in the 1KG GWAS in a multiple instrument approach for the MR analyses (n=52 SNPs). Additionally, we separately studied the effect of rs2794520 at the CRP locus to minimize the probability of horizontal pleiotropy that may be introduced in a multiple instrument approach. We tested the statistical significance of the association between the instrument and CRP using the formula: R 2 is the variance explained of CRP by the genetic instrument (0.014 for the rs2794520 SNP and 0.065 for the 52-SNP score), n is the number of individuals included in the CRP GWAS, and k the number of variants included in the genetic score. The F statistic for the 52-SNP score was 273, and for the rs2794520 SNP 2,902, indicating that both instruments were strong.
For the clinical outcomes, we used summary statistics from the most recent meta-analysis of GWA studies. For diastolic and systolic blood pressure, we used data from the UK Biobank. The details of the outcome studies are summarized in Table S12 . We implemented four different methods of MR analyses: Inverse-variance weighted method (IVW), MR-Egger, Weighted median (WM), and Penalized weighted median (PWM). We used the "TwoSampleMR" package in R for the MR analyses 33 . Further, we applied the Bonferroni method to correct for multiple testing (0.05/9 phenotypes = 5.6×10 -3 ). When the Qstatistic of the IVW analyses provided evidence for heterogeneity, the weighted median estimates were used for significance. The MR methods are described briefly below.
Inverse-variance weighted (IVW): The causal estimate is obtained by regressing the SNP associations with the outcome on the SNP associations with the risk factor, with the intercept set to zero and weights being the inverse-variances of the SNP associations with the outcome. With a single genetic variant, the estimate is the ratio of coefficients betaY/betaX and the standard error is the first term of the delta method approximation betaYse/betaX. When all CRP-SNPs are valid IVs, the IVW estimates converge to the true causal effect. When one or more invalids IVs are present, (ie. one SNP has effect on outcome through a different pathway than CRP), the IVW estimate deviates from the true causal effect.
MR-Egger:
We used MR-Egger to account for potential unbalanced pleiotropy in the multiple variant instrument 34 . When unbalanced pleiotropy is present, an alternative effect (positive or negative) is present between the SNP and the outcome that may bias the estimate of the causal association. The MR-Egger method is similar to the IVW analysis, but does not force the intercept to pass through the origin.
The slope of the MR-Egger regression provides the estimate of the causal association between CRP and the clinical outcome. An MR-Egger intercept that is significantly different from zero suggests directional pleiotropic effects that may bias uncorrected estimates of the causal effect. MR-Egger regression depends on the InSIDE (Instrument Strength Independent of Direct Effect) assumption, that states that the strengths of the effect of the SNP on the outcome is uncorrelated with the direct pleiotropic effect of the SNP on the outcome.
Weighted median (WM) and penalized Weighted Median (PWM): We applied the median based method to provide robust estimates of causal association even in the presence of horizontal pleiotropy when up to 50% of the information contributed by the genetic variants is invalid 35 . In PWM analysis the effect of each variants is weighted by a factor that corresponds to the Q statistics (heterogeneity test) of the SNP; this means that most variants will not be affected by this correction, but the causal effect of the outlying variants, which are most likely to be invalid IVs, will be down-weighted.
We displayed the individual SNP causal effect estimates and corresponding 95% confidence intervals in a forest plot. To assess whether one of the variants used in the genetic score had disproportionate effects, we performed "leave-one-out" analyses where one SNP at a time is removed from the score. We depicted the relationship between the SNP effect on CRP and the SNP effect on the clinical outcomes in a scatter plot, and plotted the individual SNP effect against the inverse of their standard error in a funnel plot. When unbalanced pleiotropy is absent, the causal effect estimates of the individual should center around the meta-analysis estimate in the funnel plot.
We used the proportion of variance in CRP explained by the genetic instruments (0.014 for the rs2794520 SNP and 0.065 for the 52-SNP score) to perform power calculations for each outcome using the online tool mRnd 36 . We calculated the power to detect a relative 5%, 10%, 15%, and 20% difference in outcome risk. For example, a 10% difference refers to an OR of at least 0.90 or 1.10 in outcome risk (Table S13) .
Results
HapMap GWAS meta-analysis for CRP levels
The HapMap meta-analysis identified 3,977 genome-wide significant variants at P<5×10 -8 (QQ-plot Figure S1 ; Manhattan plot Figure S2 ), which mapped to 48 distinct loci ( Table 1, Table S3 ). Of the previously reported 18 variants for CRP, 16 remained associated. Compared to the previous GWAS, the rs6901250 variant at the GPRC6A locus (P=0.09) and the rs4705952 variants at the IRF1 locus (P=2.7×10 -3 ) were not significant. The beta estimates for natural log-transformed CRP for each of the associated loci ranged from 0.020 to 0.229. We observed the strongest association for rs2794520 at the CRP gene (β=0.182 in the natural log-transformed CRP (mg/L) per copy increment in the coded allele, P=4.17×10 -523 ), followed by rs4420638 at the APOC1/E gene (β=0.229, P=1.23×10 -305 ). Similarly to previous GWAS meta-analysis, the lead variant within the interleukin-6 receptor gene (IL6R) was rs4129267 (β=0.088, P=1.2×10 -129 ). Related to the interleukin-6 pathway, we identified rs1880241 upstream of the IL6 gene (β= 0.028, P=8.4×10 -14 ) . In addition to the previously described interleukin-1 signaling, the IL1RN-IL1F10 locus (interleukin-1 receptor antagonist and interleukin-1 family member 10), we found rs9284725 within the interleukin-1 receptor 1 gene (IL1R1, β=0.02, P=7.3×10 -11 , Table 1 ). The sex-specific meta-analyses did not identify additional loci for CRP compared to the overall meta-analysis including both sexes.
However, at four genetic variants we found evidence for heterogeneity in effect estimates between women and men (Table S4) , though the directions of associations were consistent.
1KG GWAS meta-analysis for CRP levels
In the 1KG meta-analysis, 8,002 variants were associated with CRP at P<5×10 -8 (QQ-plot Figure S3 ;
Manhattan plot Figure S4 ). This resulted in 40 distinct loci, of which 36 overlapped with the HapMap meta-analysis ( Table 1 ). The lead variant at the CRP locus in the 1KG GWAS was rs4287174 (β=-0.185, P=1.95× -398 ), which is in high LD with rs2794520 (r 2 =0.98), the lead variant at the CRP locus in the HapMap GWAS. Among eight of the overlapping loci, the lead variant was at the same position in both GWAS (rs1260326, rs1490384, rs10832027, rs1582763, rs7310409, rs2239222, rs340005, and rs1800961). Compared with HapMap, the four additional variants identified in 1KG were rs75460349, rs1514895, rs112635299, and rs1189402. The variants rs1514895 and rs1189402 were available in the HapMap GWAS, but were not associated at the genome-wide threshold (respectively P=1.2×10 -7 and P=8.1×10 -3 ). The two variants rs75460349 and rs112635299 were not available in the HapMap GWAS, nor were variants in high LD (r 2 <0.8). The rs75460349 is a low frequency variant with a coded allele frequency of 0.97 (β=0.086, P=4.5×10 -10 ). Also rs112635299 near the SERPINA1/2 gene is a low frequency variant with a MAF of 0.02 (β=0.107, P=2.1×10 -10 ). Adjustment for BMI in the 1KG GWAS (n=147,827) revealed six additional loci that were not associated with CRP in the HapMap and 1KG primary analyses (Table 1 ; Table S5 , QQ-plot Figure S5 ; Manhattan plot Figure S6 ). The associations at three lead variants were much reduced after adjustment for BMI (rs1558902 (FTO), Padjusted=0.40; rs12995480 (TMEM18), Padjusted=0.02; rs64343 (ABO), Padjusted =1.0×10 -7 ). Both the FTO and TMEM18 gene are well-known obesity genes. Except for the FTO, TMEM18, and ABO loci, all distinct loci identified in the primary 1KG analysis were also associated with CRP in the BMI adjusted 1KG analysis.
No genome-wide significant association was observed on the X-chromosome in the 1KG GWAS including 102,086 individuals.
LD score regression
The HapMap GWAS LD Score regression intercept was 1.03 (standard error: 0.013), and the 1KG intercept was 1.02 (standard error 0.011). This suggests that a small proportion of the inflation is attributable to confounding bias (~12% for the HapMap GWAS and ~13% for the 1KG GWAS). Hence, the vast majority of inflation is due to the polygenic architecture of circulating CRP levels. As depicted in Figure 1 , CRP showed strong positive genetic correlations with anthropometric traits (e.g., BMI: Rg=0.43, P=5.4×10 -15 ), glycemic phenotypes (e.g., type 2 diabetes Rg=0.33, P=3.1×10 -6 ), lipid phenotypes (e.g., triglycerides Rg=0.29, P=7.9×10 -5 ), and coronary artery disease (Rg=0.23, P=2.4×10 -5 ) (Table S6 ). By comparison, CRP showed inverse genetic correlations with educational attainment (e.g., college completion Rg=-0.27, P=9.2×10 -7 ), lung function (e.g., forced vital capacity Rg=-0.24, P=4.6×10 -12 ), and HDL-cholesterol (Rg=-0.30, P=4.8×10 -9 ).
Additional signals at distinct loci
Approximate conditional analyses in the 1KG GWAS revealed additional signals at nine loci (Table S7) .
Five loci showed one secondary signal (IL6R, NLRP3, HNF1A, CD300LF, and APOE/APOC1), the PPP1R3B locus had two additional signals, the LEPR locus had three additional signals, and the SALL1 locus had four additional signals, whereas the CRP locus showed a total of 13 distinct associated variants.
Interestingly, the rs149520992 rare variant (MAF=0.01) mapping to the CRP locus showed an association at Pconditional=3.7×10 -15 with β=-0.272 for the T-allele. The GCTA effect estimates for the ten distinct variants in the vicinity of the CRP gene identified in the 1KG conditional analysis are in high correlation with the effect estimates of these variants obtained from the RS-I and WGHS individual level data (rRS=0.97, and rWGHS=0.84), confirming the reliability of the GCTA estimates.
Variance explained of CRP
The lead variant at the CRP locus in both the HapMap (rs2794520) and 1KG (rs4287174) GWAS explained 1.4% of the variance in natural log-transformed CRP levels. The distinct variants at the CRP locus derived from the joint conditional analysis in the 1KG GWAS explained 4.3% of the variance. The lead variants at all distinct loci together explained 6.2% of the CRP variance in the HapMap GWAS, and 6.5% in the 1KG GWAS. When we added the distinct variants at associated loci derived from the conditional analysis, the variance explained by all associated loci was 11.0% in the 1KG GWAS.
Functional annotation
We applied DEPICT and MAGMA analyses for functional annotation and biological interpretation of the findings. The DEPICT analysis included 9,497 genome-wide significant variants, covering 283 genes, and prioritized 55 candidate genes across 29 regions (FDR<0.05, Table S8 ). The prioritized genes included IL6R mapping to the 1q21.3 locus (represented by rs4129267) and APCS to the 1q32.2 locus. Investigating 10,968 reconstituted gene sets for enrichment, DEPICT highlighted 583 (5.3%) gene sets to be significantly enriched among CRP-associated loci at FDR<0.05 (Table S9) . Using further clustering, we identified 66 groups of gene sets that substantially correlated and clustered in two sets, one mainly comprised of immune pathways, and the other enriched for metabolic pathways (Figure 2 ). In Figure 3 , we present the prioritized genes and the most significant gene sets. We found synovial fluid, liver tissue, and monocytes to be enriched for the expression of the prioritized genes (FDR<0.05). The MAGMA analysis was applied on the HapMap GWAS, identifying five significantly enriched gene sets (Bonferronicorrected P<0.05, Table S10 ). Results included consequences of gene EGF induction, positive regulation of gene expression, and IL-6 signaling pathway, in line with the most strongly prioritized gene from DEPICT gene prioritization. MAGMA analysis prioritized liver as a sole enriched tissue (P=0.048).
To prioritize the most likely trait-relevant gene for each GWAS locus, we interrogated the GWAS data with cis-eQTL data identified from 44 post-mortem tissues and a large whole blood eQTL metaanalysis using colocalization analysis (Table S11 ). Figure S7 presents the GWAS loci that colocalize with cis-eQTLs with the corresponding tissue, the colocalizing gene, and the posterior probability of one shared underlying variant driving both associations. Out of the 58 lead gSNPs, 25 SNPs (43%) showed evidence of colocalization with one or more local eQTL effects (posterior probability >0.9). For example, the rs2293476 locus colocalizes with several cis-eQTL effects for PABC4, and pseudogenes OXCT2P1, RP11−69E11.4, and RP11−69E11.8. The rs10925027 locus shows colocalization with cis-eQTL effect for NLRP3, exclusively in the highly powered blood meta-analysis. Out of 25 loci, for nine loci there was only one colocalizing gene. Altogether, gSNP-associated cis-eQTL effects were present in up to 14 different tissues, with whole blood, esophagus mucosa, skin, and tibial nerve being the most frequent.
Mendelian randomization analyses
We observed a protective effect of genetically determined variance in CRP with schizophrenia with an IVW odds ratio (OR) of the 52-SNP score of 0.89 (95%CI: 0.81-0.97, P=6.6×10 -3 ) (Tables S14-S15, Figure S8 -S11). The MR-Egger intercept was compatible with no unbalanced pleiotropy (P=0.48). The estimate of the rs2794520 variant was comparable to the 52-SNP score estimate (OR 0.89, 95% CI 0.84-0.94, P=0.046). The WM and PWM estimates were comparable to the IVW estimate (ORWM 0.89, PWM=5.1×10 -3 ; ORPWM 0.89, PPWM=4.4×10 -3 ). The "leave-one-out" analysis provided evidence that no single variant was driving the IVW point estimate ( Figure S10 ). The causal OR between the rs2794520 variant and BD was 1.33 (95% CI 1.03-1.73, P=0.032). For the 52-SNP score, the IVW OR was 1.16 We observed evidence against a causal association between either CRP rs2794520 (OR 1.01, 95%CI 0.91-1.12, P=0.88), or the 52-SNP instrument (OR 0.96, 95%CI 0.84-1.09, P=0.51) and CAD. An Egger intercept of 0.014 suggested presence of unbalanced pleiotropy (P=5.8×10 -3 ), with an MR-Egger causal estimate of OR 0.79 (95%CI 0.67-0.94, P=0.012). However, the WM and PWM showed no association between CRP and CAD. For AD, there was evidence against an association with rs2794520 (P=0.592), though the IVW OR showed a protective effect (OR 0.51, 95%CI 0.30-0.88, P=0.015). The Egger intercept of 0.046 suggested unbalanced pleiotropy (P=0.042), and the MR-Egger OR was 0.27 (95%CI 0.12-0.60). However, the association was null for the WM and PWM analyses (ORWM 1.04, PWM=0.61; ORPWM 1.05, PPWM=0.53). We observed evidence against an effect for CD, DBP, IBD, RA, and SBP for the rs2794520 variant and the IVW, MR-Egger, WM, and PWM analyses.
Discussion
Using genomic data from >200,000 individuals, we have identified 58 distinct signals for circulating CRP levels, confirming 16 previously identified CRP loci. BMI-adjusted GWAS suggested that the vast majority of genetic risk variants affect CRP levels independent of its main determinant (BMI). The genome-wide in silico functional annotation analysis highlights 55 genes which are likely to explain the association of 29 signals to CRP levels. The data identified gene sets involved in the biology of immune system and liver as main regulators of serum CRP levels. Mendelian randomization analyses supported causal associations of genetically increased CRP with a protective effect on schizophrenia, and increased risk of bipolar disorder.
Obesity is one of the main determinants of chronic low-grade inflammation in the general population 37; 38 . Adjustment for BMI in the CRP GWAS abolished the association at only three lead variants, suggesting that the genetic regulation of chronic low-grade inflammation is largely independent from BMI. Notably, BMI adjustment resulted in the identification of six variants that were not associated with CRP in the BMI-unadjusted GWAS. This supports the notion that adjustment for covariates that explain phenotypic variance may improve the statistical power in linear model analyses of quantitative traits 39 . Although adjustment for heritable correlated traits in GWAS may bias effect estimates (collider bias) 40 , there is consistent evidence in the literature that BMI has a causal direct effect on CRP levels 41 , and therefore, collider bias in CRP GWAS adjusted for BMI is less likely.
The sex-stratified analyses revealed significant heterogeneity in effect estimates between men and women at only four lead variants, which represent less than 10% of all CRP loci. Even among these four loci the effect directions were similar, thus the heterogeneity was limited to effect sizes. The data suggest that the difference between men and women in CRP levels is less likely to be explained by genetic factors. Furthermore, two signals identified in the former HapMap GWAS of CRP levels were not significant in the current HapMap GWAS. The effect estimates in the current analyses were too small to identify with our sample size.
The top variant at the CRP locus in both the HapMap and 1KG GWAS explained 1.4% of the variance in circulating CRP levels. The approximate conditional analysis resulted in 13 variants jointly associated within the CRP locus in the 1KG GWAS. With respect to locus definition, we used a conservative distance criterion compared to other GWA studies that often use ±500kb surrounding the GWAS peak 42 . Here, we used the criterion that the minimum distance between the boundaries of loci is 500kb. In order to identify further variants associated with CRP levels, we performed approximate conditional analyses resulting in multiple putative additional variants, also inside and near genes that were not identified in the primary GWAS. As an example, the CRP locus spanned >2MB according to our criterion. Approximate conditional analysis revealed that two variants, namely rs3027012 near DARC and rs56288844 near FCER1A, both downstream of the CRP gene, were associated with CRP levels.
Furthermore, upstream of CRP, we identified a variant near FCGR2A (Immunoglobulin G Fc Receptor II).
These results show that for a given lead variant, potentially multiple causal loci, here DARC, FCER1A, and FCGRA2, alongside CRP contribute to chronic low-grade inflammation and variation in circulating CRP levels.
DEPICT analysis provided further evidence that the genes annotated to the associated CRP variants mainly cluster in the immune and liver biological systems. Notably, the gene set "inflammatory response", which captures both immune response and liver metabolism, was the main connector network between the two networks. This is in line with the observation that CRP is mainly produced by liver cells in response to inflammatory cytokines during acute and chronic inflammation 43 . Interestingly, the analysis highlighted iron homeostasis as an enriched gene set. In agreement, the conditional analysis highlighted a distinct genetic association at the hemochromatosis gene HFE, a transmembrane protein of the major histocompatibility complex (MHC) class I family. Previous studies show that iron metabolism plays a pivotal role in inflammation 44; 45 . However, genetic pleiotropy may highlight co-regulated networks in pathway analysis that are not causal to inflammation per se. It is also important to note that the results of DEPICT analyses apply to reconstituted gene sets which may sometimes have slightly different overlaying biological theme than the original gene set annotation.
The MR analyses validate previous evidence that genetically-elevated CRP is protective for the risk of schizophrenia 13; 46 , although observational data suggest a positive association between CRP and risk of schizophrenia 47 . For bipolar disorder we observed a positive causal effect, which is in line with previous MR and observational studies 13; 48 . Although the causal underlying mechanisms remain to be elucidated, a hypothesis for the schizophrenia observation might be the immune response to infections early in life. Levels of acute-phase response proteins in dry blood spots collected at birth are lower for patients with non-affective psychosis, which includes schizophrenia, compared to controls, suggesting a weaker immune response at birth 49 . Also, neonates that have been exposed to a maternal infection and have low levels of acute-phase response proteins, have a higher risk of schizophrenia 50 . Altogether, the evidence suggests that a deficient immune response may contribute to chronic infection in children and the development of schizophrenia. For AD and CAD, the Egger intercept showed evidence of unbalanced pleiotropy and the Egger estimate showed a protective effect of CRP on the risk of AD and CAD.
However, for both outcomes, the effects of the WM and PWM analyses, as well as analyses using the single rs2794520 variant (which is least likely to be affected by pleiotropy) were null. The MR-Egger estimate relies on the InSIDE assumption which states that the strength of the association between the genetic variants and CRP is independent from the strength of the direct pleiotropic effects of the genetic variants on the outcome. This assumption may be violated when the genetic variants are associated with a confounder of the CRP-outcome association. Such a scenario may occur when the genetic variants are associated with an exposure that is causally upstream of the exposure under study. In the context of the association of CRP with AD and CAD, this could be lipids or glycemic phenotypes. Several genetic variants used in the 52-SNP instrument are associated with metabolic phenotypes that may affect CRP levels. In agreement, the WM and PWM, in which the InSIDE assumption is relaxed, and the single variant analysis showed no association. Furthermore, the observation that CRP is not causally related to CAD in the MR analyses is in comparison to previous published studies 51 . Power calculation showed that we had 100% power to detect a 10% difference in CAD risk, thus the probability of a false negative finding is small. Also, CRP is associated with future CAD in observational studies, and randomized trials have shown a beneficial effect of lowering inflammation using statins 52 and canakinumab 53 on CAD risk, but this effect is unlikely to be attributable to CRP.
The strengths of our study are the use of a very large sample size for CRP and the use of both HapMap and 1KG imputed data. Furthermore, we conducted sex-specific and BMI-adjusted analyses to study the effect of sex and body mass on the associations between genetic variants and CRP. To maximize power and to efficiently use the data, we meta-analyzed all available samples in a discovery setting without replication. The consistent association of the variants in >50 studies at a strict Bonferroni corrected threshold provide confidence that our findings represent true associations. We used both HapMap and 1KG imputed data to identify genetic variants for circulating CRP levels. At the start of the project, more studies had HapMap imputed data available. Hence, the sample size and thus power in the HapMap GWAS was higher compared to the 1KG. Also, HapMap may identify variants that are not identified in 1KG GWAS 54 . Nevertheless, 1KG offers better coverage of uncommon variants and includes INDELs, which are not included in the HapMap reference panel. Including both reference panels, we used all available samples and maximized the possibility to identify genetic variants for CRP, both common and uncommon.
However, we note limitations to our study. GWAS merely identify loci associated with complex phenotypes and the identification of causal genes remains challenging. We only included individuals of European ancestry; the generalizability of our findings to other races/ethnicities is uncertain. In addition, although our analyses provided support for causal associations, we acknowledge that we may not have identified the causal variants and we may not have eliminated residual confounding. The colocalisation analyses provide evidence for colocalisation of CRP GWAS signals and eQTLs, however, it does not provide evidence that the GWAS signal is functioning on CRP through the gene expression. We further note that the method assumes identical LD-structure from the GWAS and eQTL datasets. As there are ~14% of non-European samples in the full GTEx dataset, this assumption might be violated for some tissues. Last, we meta-analyzed all available samples in one meta-analysis and did not replicate our findings in an independent sample. Therefore, our findings may need replication.
In conclusion, we performed a large GWAS meta-analysis to identify genetic loci associated with circulating CRP levels, a sensitive marker of chronic low-grade inflammation, and found support for a causal role of CRP with a decreased risk of schizophrenia and higher risk of bipolar disorder. As inflammation is implicated in the pathogenesis of multiple complex diseases, the new insights into the biology of inflammation obtained in the current study may contribute to future therapies and interventions. 
